查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1407338

运甲状腺素蛋白淀粉样变性治疗市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按类型、治疗、疾病类型、配销通路、地区、竞争细分

Transthyretin Amyloidosis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Therapy, By Disease Type, By Distribution Channel, By Region, By Competition
出版日期: | 出版商: TechSci Research | 英文 179 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年，全球转甲状腺素蛋白淀粉样变性治疗市场价值为 49.5 亿美元，预计在预测期内将强劲增长，到 2028 年CAGR为6.28%。这一增长归因于新疗法开发的广泛研究以及市场的存在。用于治疗转甲状腺素蛋白的强大管道药物。它是一种罕见的进行性疾病，其特征是身体器官和组织中异常蛋白质（例如misTTR）的沉积。与此疾病相关的症状主要取决于所涉及的器官，例如手臂的心皮综合症、背部的腰椎管狭窄、头部和颈部的玻璃体混浊以及脚部的肿胀。转甲状腺素蛋白淀粉样变性有两种主要类型，例如突变/遗传性 ATTR 和野生型 ATTR。它经常影响身体的主要器官，如肝臟、肾臟、神经和心臟。然而，发展中国家缺乏先进的诊断设施是转甲状腺素蛋白淀粉样变性治疗市场成长的主要挑战。

主要市场驱动因素

提高疾病意识

市场概况
预测期 2024-2028
2022 年市场规模 49.5亿美元
2028 年市场规模 70.6亿美元
2023-2028 年CAGR 6.28%
成长最快的细分市场 亚太地区
最大的市场 北美洲

全球转甲状腺素蛋白淀粉样变性治疗市场的成长与疾病意识的策略增强密切相关。随着意识的提高，早期诊断和治疗开始同步增加。这反过来又促进了对治疗干预措施的更高需求，并推动市场扩张。提高疾病意识是患者和医疗保健提供者教育的催化剂，有助于就可用的治疗方案做出明智的决策。这种意识的提高不仅减少了诊断滞后，而且推动了积极主动的方法来管理转甲状腺素蛋白淀粉样变性。认识到这一趋势的製药公司可以透过投资有针对性的行销活动和教育活动来利用不断增长的市场。此外，消息灵通的患者群体更有可能积极寻求医疗援助，从而扩大了接受治疗干预的患者群体。由此产生的需求激增不仅增加了市场收入，也刺激了创新新型治疗解决方案的研发工作。从本质上讲，提高疾病意识、早期诊断和对治疗方式的需求增加之间的共生关係构成了全球转甲状腺素蛋白淀粉样变性治疗市场持续成长的基石。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球运甲状腺素蛋白淀粉样变性治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（ATTR-PN、ATTR-CM）
    • 透过治疗（标靶治疗（Onpattro、Inotersen、Vyndaqel/Vyndamax）、支持治疗、管道治疗）
    • 依疾病类型（遗传性运甲状腺素蛋白淀粉样变性（多发性神经病变、心肌病变、混合型）、野生型淀粉样变性）
    • 按配销通路（医院药房、专科药房、零售药房、网路药房）
    • 按地区（北美、欧洲、亚太地区、南美、中东和非洲）
    • 按公司划分 (2022)
  • 市场地图
    • 按类型
    • 透过治疗
    • 依疾病类型
    • 按配销通路
    • 按地区

第 6 章：北美运甲状腺素蛋白淀粉样变性治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（ATTR-PN、ATTR-CM）
    • 透过治疗（标靶治疗（Onpattro、Inotersen、Vyndaqel/Vyndamax）、支持治疗、管道治疗）
    • 依疾病类型（遗传性运甲状腺素蛋白淀粉样变性（多发性神经病变、心肌病变、混合型）、野生型淀粉样变性）
    • 按配销通路（医院药房、专科药房、零售药房、网路药房）
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲运甲状腺素蛋白淀粉样变性治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（ATTR-PN、ATTR-CM）
    • 透过治疗（标靶治疗（Onpattro、Inotersen、Vyndaqel/Vyndamax）、支持治疗、管道治疗）
    • 依疾病类型（遗传性运甲状腺素蛋白淀粉样变性（多发性神经病变、心肌病变、混合型）、野生型淀粉样变性）
    • 按配销通路（医院药房、专科药房、零售药房、网路药房）
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章：亚太地区运输甲状腺素蛋白淀粉样变性治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（ATTR-PN、ATTR-CM）
    • 透过治疗（标靶治疗（Onpattro、Inotersen、Vyndaqel/Vyndamax）、支持治疗、管道治疗）
    • 依疾病类型（遗传性运甲状腺素蛋白淀粉样变性（多发性神经病变、心肌病变、混合型）、野生型淀粉样变性）
    • 按配销通路（医院药房、专科药房、零售药房、网路药房）
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲运甲状腺素蛋白淀粉样变性治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（ATTR-PN、ATTR-CM）
    • 透过治疗（标靶治疗（Onpattro、Inotersen、Vyndaqel/Vyndamax）、支持治疗、管道治疗）
    • 依疾病类型（遗传性运甲状腺素蛋白淀粉样变性（多发性神经病变、心肌病变、混合型）、野生型淀粉样变性）
    • 按配销通路（医院药房、专科药房、零售药房、网路药房）
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲运甲状腺素蛋白淀粉样变性治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（ATTR-PN、ATTR-CM）
    • 透过治疗（标靶治疗（Onpattro、Inotersen、Vyndaqel/Vyndamax）、支持治疗、管道治疗）
    • 依疾病类型（遗传性运甲状腺素蛋白淀粉样变性（多发性神经病变、心肌病变、混合型）、野生型淀粉样变性）
    • 按配销通路（医院药房、专科药房、零售药房、网路药房）
    • 按国家/地区
  • MEA：国家分析
    • 南非运甲状腺素蛋白淀粉样变性治疗
    • 沙乌地阿拉伯运输甲状腺素蛋白淀粉样变性治疗
    • 阿联酋运甲状腺素蛋白淀粉样变性治疗

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第 13 章：全球运输甲状腺素蛋白淀粉样变性治疗市场：SWOT 分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • 辉瑞公司
    • Business Overview
    • Product Offerings
    • Recent Developments
    • Financials (As Reported)
    • Key Personnel
    • SWOT Analysis
  • 强生服务公司
  • 伊奥尼斯製药公司
  • Alnylam 製药公司
  • BridgeBio 製药公司
  • 百时美施贵宝公司。
  • Acrotech 生物製药。
  • 阿斯特捷利康公司
  • SOM 生物技术。

第 16 章：策略建议

简介目录
Product Code: 20213

Global Transthyretin Amyloidosis Treatment Market has valued at USD 4.95 Billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 6.28% through 2028. The growth is attributed to the extensive research in the development of new therapies and the presence of robust pipeline drugs that are used to treat transthyretin. It is a rare and progressive disease characterized by the deposition of abnormal proteins such as misTTR in organs and tissue of the body. The symptoms associated with the disease mainly depend on the organs that are involved such as carpel syndrome for arms, lumbar spinal stenosis for the back, vitreous opacities for the head and neck, and swelling at the feet. There are two major types of transthyretin amyloidosis such as mutated/ hereditary ATTR and wild-type ATTR. It often affects major organs of the body such as the liver, kidney, nerves, and heart. However, the unavailability of advanced diagnostic facilities in developing countries is a major challenge to the transthyretin amyloidosis treatment market growth.

Key Market Drivers

Increasing Disease Awareness

Market Overview
Forecast Period2024-2028
Market Size 2022USD 4.95 Billion
Market Size 2028USD 7.06 Billion
CAGR 2023-20286.28%
Fastest Growing SegmentAsia Pacific
Largest MarketNorth America

The growth of the Global Transthyretin Amyloidosis Treatment Market is intricately linked to the strategic enhancement of disease awareness. As awareness increases, there is a simultaneous uptick in early diagnosis and treatment initiation. This, in turn, fosters a higher demand for therapeutic interventions, propelling market expansion. Elevated disease awareness serves as a catalyst for patient and healthcare provider education, facilitating informed decision-making regarding available treatment options. This heightened awareness not only reduces diagnostic lag but also fuels a proactive approach towards managing transthyretin amyloidosis. Pharmaceutical companies, recognizing this trend, can capitalize on the growing market by investing in targeted marketing campaigns and educational initiatives. Moreover, a well-informed patient population is more likely to actively seek medical assistance, leading to an augmented patient pool for treatment interventions. The resultant surge in demand not only bolsters the market's revenue but also stimulates research and development efforts to innovate novel therapeutic solutions. In essence, the symbiotic relationship between increasing disease awareness, early diagnosis, and heightened demand for treatment modalities forms the cornerstone for the sustained growth of the Global Transthyretin Amyloidosis Treatment Market.

Advancements in Diagnostic Technologies

The growth trajectory of the Global Transthyretin Amyloidosis Treatment Market is poised to ascend with the integration of cutting-edge diagnostic technologies. Advancements in diagnostic tools not only facilitate swift and accurate disease identification but also enable a more nuanced understanding of individual patient profiles. This precision in diagnosis is instrumental in tailoring targeted treatment strategies, thereby propelling the demand for specialized therapeutics. Sophisticated diagnostic technologies, such as genetic testing and biomarker identification, empower healthcare professionals to identify transthyretin amyloidosis at earlier stages, fostering timely intervention. Early detection, in turn, correlates with improved treatment outcomes and patient prognosis. This positive correlation incentivizes both healthcare providers and patients to adopt these advanced diagnostic tools, creating a conducive environment for market expansion. Furthermore, the integration of innovative diagnostic technologies stimulates research and development initiatives, driving continuous improvement in treatment modalities. Pharmaceutical companies, in response to evolving diagnostic capabilities, are incentivized to invest in novel therapies, creating a cycle of innovation that contributes to the overall growth of the market. In essence, the synergy between diagnostic advancements and therapeutic interventions forms a pivotal driver for the Global Transthyretin Amyloidosis Treatment Market.

Patient Advocacy and Support Groups

The growth of the Global Transthyretin Amyloidosis Treatment Market is significantly influenced by the pivotal role played by patient advocacy and support groups. These groups serve as catalysts for heightened disease awareness, patient education, and community engagement. By fostering a sense of community among individuals affected by transthyretin amyloidosis, these advocacy groups create a platform for shared experiences and information exchange. Patient advocacy groups contribute to market growth by actively participating in awareness campaigns, encouraging early diagnosis, and promoting treatment options. Their influence extends to shaping healthcare policies and driving research initiatives, thereby creating an environment conducive to the development and adoption of innovative therapies. Moreover, the collaboration between patient advocacy groups and pharmaceutical companies enhances the development and accessibility of treatment options. By incorporating patient perspectives, these collaborations ensure that therapeutic solutions align with the needs and preferences of the affected community. This not only aids in the market penetration of treatments but also cultivates a supportive ecosystem that encourages patient adherence and long-term engagement with healthcare services. In essence, the symbiotic relationship between patient advocacy and the Global Transthyretin Amyloidosis Treatment Market underscores the significance of a united front in driving awareness, research, and ultimately, the overall growth of the market.

Key Market Challenges

Limited Treatment Options

The growth of the Global Transthyretin Amyloidosis Treatment Market faces a substantial hindrance due to the challenge of limited treatment options. The scarcity of diverse therapeutic interventions constrains the market's potential for expansion, as it narrows the choices available for both healthcare providers and patients. This constraint not only limits the ability to address the varied needs of individuals but also hampers the overall efficacy of managing transthyretin amyloidosis. The lack of treatment diversity poses a barrier to market growth by reducing competitive dynamics among pharmaceutical companies. A dearth of alternative therapies may result in limited innovation and slower development of new treatment modalities. Additionally, it heightens the risk of treatment resistance and suboptimal outcomes for patients, impacting their confidence in available therapeutic solutions. Moreover, from a business perspective, the constrained treatment landscape diminishes the revenue potential for pharmaceutical companies operating in this market. The competitive edge that a diverse product portfolio provides is compromised, impacting market share and profitability.

Diagnosis Challenges

The growth trajectory of the Global Transthyretin Amyloidosis Treatment Market faces impediments due to the substantial challenges associated with diagnosis. The intricate nature of transthyretin amyloidosis often leads to delayed or inaccurate diagnoses, hindering timely intervention and treatment initiation. The complexity of symptoms and the overlap with other medical conditions pose challenges for healthcare professionals, resulting in a diagnostic lag that impacts patient outcomes. Diagnostic challenges contribute to a cascade of issues for the market. Firstly, delayed diagnosis limits the patient pool seeking treatment, restricting market demand. Secondly, the lack of standardized diagnostic protocols hampers the efficiency of clinical trials and research initiatives, impeding the development of new treatment modalities. Additionally, the uncertainty associated with accurate diagnosis may lead to suboptimal treatment choices, affecting patient satisfaction and long-term engagement with therapeutic interventions. From a business perspective, the diagnostic hurdles create a barrier for pharmaceutical companies aiming to position their treatments effectively in the market. The market's potential for growth is constrained by the critical need for streamlined, accurate diagnostic tools that facilitate early and precise identification of transthyretin amyloidosis. Addressing these diagnostic challenges is pivotal for unlocking the full growth potential of the Global Transthyretin Amyloidosis Treatment Market.

Key Market Trends

Advancements in Gene Therapies

The growth trajectory of the Global Transthyretin Amyloidosis Treatment Market is poised for acceleration with the advent of groundbreaking advancements in gene therapies. Innovations in gene-based interventions hold immense promise for revolutionizing the treatment landscape of transthyretin amyloidosis. Gene therapies have the potential to address the root cause of the disease at a molecular level, providing a paradigm shift towards more targeted and efficacious treatment options. The development of gene therapies not only enhances the therapeutic arsenal but also attracts substantial investment and research interest, fostering a competitive market environment. These advancements open new avenues for pharmaceutical companies to differentiate their offerings and tap into a rapidly expanding market segment. Furthermore, gene therapies showcase the potential to provide durable and transformative outcomes for patients, creating a compelling value proposition for both healthcare providers and individuals affected by transthyretin amyloidosis. The growing focus on precision medicine and personalized treatment approaches aligns with the inherent capabilities of gene therapies, driving increased adoption and market penetration. In essence, the integration of advanced gene therapies stands as a key driver propelling the growth of the Global Transthyretin Amyloidosis Treatment Market, heralding a new era of targeted and innovative solutions for this complex and challenging medical condition.

Targeted Therapies and RNA Interference

The Global Transthyretin Amyloidosis Treatment Market is poised for dynamic growth fueled by the emergence of targeted therapies and RNA interference (RNAi) technologies. Targeted therapies, designed to specifically address the underlying mechanisms of transthyretin amyloidosis, offer a more precise and effective treatment approach. This focus on the root cause enhances therapeutic outcomes, reducing side effects and improving overall patient satisfaction. RNA interference, a revolutionary technology that enables the selective silencing of disease-causing genes, holds immense promise for transthyretin amyloidosis. By suppressing the production of aberrant transthyretin protein, RNAi therapies have the potential to halt disease progression at the molecular level. This innovative approach not only diversifies the treatment landscape but also positions the market for significant expansion. The strategic integration of targeted therapies and RNA interference aligns with the industry's trend toward personalized medicine, catering to the unique genetic and molecular profiles of individual patients. As pharmaceutical companies invest in research and development to bring these advanced therapies to market, the resulting innovation will likely drive substantial revenue growth, fostering a competitive and dynamic Global Transthyretin Amyloidosis Treatment Market. In essence, the convergence of targeted therapies and RNA interference technologies marks a transformative phase, shaping the future of transthyretin amyloidosis treatment on a global scale.

Segmental Insights

Disease Type Insights

Based on the Disease Type, the Hereditary transthyretin amyloidosis segment is anticipated to witness substantial market growth throughout the forecast period. The Global Transthyretin Amyloidosis Treatment Market is poised for significant growth, driven by the prevalence and recognition of hereditary transthyretin amyloidosis (hATTR). As genetic testing and diagnostic capabilities advance, there is a heightened awareness of hATTR, contributing to an expanding patient pool seeking treatment interventions. The distinct genetic basis of hATTR not only underscores the need for specialized therapies but also propels research and development efforts to address the unique challenges posed by hereditary forms of the disease. Pharmaceutical companies, recognizing the specific demands of hATTR, are investing in targeted therapeutic solutions tailored to the genetic underpinnings of the condition. This strategic focus on hereditary transthyretin amyloidosis not only ensures more effective treatments but also positions companies competitively in an evolving market landscape. Moreover, the genetic heritability of the disease emphasizes the importance of early intervention and proactive management, creating a sustained demand for treatment options. The growing prevalence of hATTR, coupled with advancements in genetic medicine, establishes a fertile ground for the expansion of the Global Transthyretin Amyloidosis Treatment Market, signaling a transformative era in addressing the hereditary aspects of this complex medical condition.

Distribution Channel Insights

Based on the Distribution Channel segment, the Hospital Pharmacies segment has been the dominant force in the market. The growth of the Global Transthyretin Amyloidosis Treatment Market is intricately linked to the pivotal role played by hospital pharmacies. As frontline healthcare providers, hospital pharmacies serve as crucial distribution hubs for specialized transthyretin amyloidosis treatments. The increasing prevalence of the condition, coupled with the demand for timely and effective interventions, positions hospital pharmacies as key contributors to market expansion. Hospital pharmacies play a central role in the continuum of care, ensuring the availability and accessibility of transthyretin amyloidosis treatments to patients within the healthcare facility. Their strategic location within hospitals streamlines the prescription fulfillment process, facilitating efficient and coordinated patient care. Moreover, hospital pharmacies often collaborate closely with healthcare professionals, enabling them to provide valuable insights into treatment options and patient adherence. This collaboration fosters a seamless integration of transthyretin amyloidosis therapies into comprehensive patient care plans. The growing reliance on hospital pharmacies as central points for medication dispensing, information dissemination, and patient support positions them as critical drivers for the sustained growth of the Global Transthyretin Amyloidosis Treatment Market. Their role in enhancing treatment accessibility and fostering a cohesive healthcare ecosystem underscores their significance in shaping the future landscape of transthyretin amyloidosis management.

Regional Insights

North America, specifically the Transthyretin Amyloidosis Treatment Market, dominated the market in 2022, primarily due to North America is poised to be a key driver of the growth in the Global Transthyretin Amyloidosis Treatment Market. The region's robust healthcare infrastructure, coupled with a high prevalence of transthyretin amyloidosis cases, positions it as a major hub for treatment advancements and market expansion. The availability of advanced diagnostic technologies and a well-established healthcare ecosystem facilitates early detection, fostering a proactive approach to managing the disease. Pharmaceutical companies in North America are at the forefront of research and development initiatives, investing in innovative therapies tailored to address the specific needs of the diverse patient population affected by transthyretin amyloidosis. The region's regulatory environment and supportive healthcare policies further expedite the approval and commercialization of novel treatments, driving market growth. Additionally, the strong presence of academic and research institutions in North America fosters collaborations that contribute to the development of cutting-edge therapeutic solutions. The region's economic prosperity and high healthcare expenditure contribute to the affordability and accessibility of transthyretin amyloidosis treatments, further fueling market expansion.

Key Market Players

Pfizer Inc.

Johnson & Johnson Services Inc.

Ionis Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc.

BridgeBio Pharma Inc.

Bristol-Myers Squibb Company.

Acrotech Biopharma.

AstraZeneca Plc.

SOM Biotech.

Report Scope:

In this report, the Global Transthyretin Amyloidosis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Transthyretin Amyloidosis Treatment Market, By Type:

  • ATTR-PN
  • ATTR-CM

Transthyretin Amyloidosis Treatment Market, By Therapy:

  • Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax)
  • Supportive Therapy
  • Pipeline Therapy

Transthyretin Amyloidosis Treatment Market, By Disease Type:

  • Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type)
  • Wild Type Amyloidosis

Transthyretin Amyloidosis Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Transthyretin Amyloidosis Treatment Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Transthyretin Amyloidosis Treatment Market.

Available Customizations:

  • Global Transthyretin Amyloidosis Treatment market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Transthyretin Amyloidosis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (ATTR-PN, ATTR-CM)
    • 5.2.2. By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)
    • 5.2.3. By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)
    • 5.2.4. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.5. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.6. By Company (2022)
  • 5.3. Market Map
    • 5.3.1 By Type
    • 5.3.2 By Therapy
    • 5.3.3 By Disease Type
    • 5.3.4 By Distribution Channel
    • 5.3.5 By Region

6. North America Transthyretin Amyloidosis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type (ATTR-PN, ATTR-CM)
    • 6.2.2. By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)
    • 6.2.3. By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)
    • 6.2.4. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Transthyretin Amyloidosis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Therapy
        • 6.3.1.2.3. By Disease Type
        • 6.3.1.2.4. By Distribution Channel
    • 6.3.2. Canada Transthyretin Amyloidosis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Therapy
        • 6.3.2.2.3. By Disease Type
        • 6.3.2.2.4. By Distribution Channel
    • 6.3.3. Mexico Transthyretin Amyloidosis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Therapy
        • 6.3.3.2.3. By Disease Type
        • 6.3.3.2.4. By Distribution Channel

7. Europe Transthyretin Amyloidosis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (ATTR-PN, ATTR-CM)
    • 7.2.2. By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)
    • 7.2.3. By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)
    • 7.2.4. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Transthyretin Amyloidosis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Therapy
        • 7.3.1.2.3. By Disease Type
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. Germany Transthyretin Amyloidosis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Therapy
        • 7.3.2.2.3. By Disease Type
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. United Kingdom Transthyretin Amyloidosis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Therapy
        • 7.3.3.2.3. By Disease Type
        • 7.3.3.2.4. By Distribution Channel
    • 7.3.4. Italy Transthyretin Amyloidosis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Therapy
        • 7.3.4.2.3. By Disease Type
        • 7.3.4.2.4. By Distribution Channel
    • 7.3.5. Spain Transthyretin Amyloidosis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Therapy
        • 7.3.5.2.3. By Disease Type
        • 7.3.5.2.4. By Distribution Channel

8. Asia-Pacific Transthyretin Amyloidosis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type (ATTR-PN, ATTR-CM)
    • 8.2.2. By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)
    • 8.2.3. By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)
    • 8.2.4. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Transthyretin Amyloidosis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Therapy
        • 8.3.1.2.3. By Disease Type
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. India Transthyretin Amyloidosis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Therapy
        • 8.3.2.2.3. By Disease Type
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. Japan Transthyretin Amyloidosis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Therapy
        • 8.3.3.2.3. By Disease Type
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. South Korea Transthyretin Amyloidosis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Therapy
        • 8.3.4.2.3. By Disease Type
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Australia Transthyretin Amyloidosis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Therapy
        • 8.3.5.2.3. By Disease Type
        • 8.3.5.2.4. By Distribution Channel

9. South America Transthyretin Amyloidosis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type (ATTR-PN, ATTR-CM)
    • 9.2.2. By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)
    • 9.2.3. By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)
    • 9.2.4. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Transthyretin Amyloidosis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Therapy
        • 9.3.1.2.3. By Disease Type
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. Argentina Transthyretin Amyloidosis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Therapy
        • 9.3.2.2.3. By Disease Type
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. Colombia Transthyretin Amyloidosis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Therapy
        • 9.3.3.2.3. By Disease Type
        • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Transthyretin Amyloidosis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type (ATTR-PN, ATTR-CM)
    • 10.2.2. By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)
    • 10.2.3. By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)
    • 10.2.4. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Transthyretin Amyloidosis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Therapy
        • 10.3.1.2.3. By Disease Type
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Saudi Arabia Transthyretin Amyloidosis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Therapy
        • 10.3.2.2.3. By Disease Type
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. UAE Transthyretin Amyloidosis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Therapy
        • 10.3.3.2.3. By Disease Type
        • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Transthyretin Amyloidosis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Pfizer Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Product Offerings
    • 15.1.3. Recent Developments
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Key Personnel
    • 15.1.6. SWOT Analysis
  • 15.2. Johnson & Johnson Services Inc.
  • 15.3. Ionis Pharmaceuticals Inc.
  • 15.4. Alnylam Pharmaceuticals Inc.
  • 15.5. BridgeBio Pharma Inc.
  • 15.6. Bristol-Myers Squibb Company.
  • 15.7. Acrotech Biopharma.
  • 15.8. AstraZeneca Plc.
  • 15.9. SOM Biotech.

16. Strategic Recommendations